Holly Hall

12PUBLICATIONS
106CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersInnate immunityCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 06, 2026
Runx1 and Runx2 act in concert to suppress Wnt/β-catenin-driven mammary tumourigenesis.

|Dec 18, 2025
Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation.

Georgios Kanellos, Chiara Giacomelli, Alexander Raven

|Feb 19, 2025
Human-correlated genetic models identify precision therapy for liver cancer.

Miryam Müller, Stephanie May, Holly Hall

|Jun 03, 2024
Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.

Sudhir B Malla, Ryan M Byrne, Maxime W Lafarge

|May 30, 2024
IL-27 maintains cytotoxic Ly6C<sup>+</sup> γδ T cells that arise from immature precursors.

Robert Wiesheu, Sarah C Edwards, Ann Hedley

|Feb 14, 2024
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.

Sudhir B Malla, Ryan M Byrne, Maxime W Lafarge

Pageof 2

Frequent Collaborators

5 joint publications

Owen J Sansom

5 joint publications

Colin Nixon

4 joint publications

Andrew D Campbell

4 joint publications

Philip D Dunne